Cover Image
市場調查報告書

院內感染性肺炎(HAP):全球臨床實驗檢討

Hospital Acquired Pneumonia (HAP) Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 321706
出版日期 內容資訊 英文 159 Pages
訂單完成後即時交付
價格
Back to Top
院內感染性肺炎(HAP):全球臨床實驗檢討 Hospital Acquired Pneumonia (HAP) Global Clinical Trials Review, H2, 2017
出版日期: 2017年09月22日 內容資訊: 英文 159 Pages
簡介

本報告提供院內感染性肺炎(HAP)的臨床試驗相關之基本資料和數據,為您彙整實驗數量及受驗者的募集情況,各階段趨勢,進行臨床試驗的主要製藥企業及研究機關簡介等資料。

簡介

  • 院內感染性肺炎(HAP)
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要5個國家的臨床實驗數量
    • 歐洲主要5個國家的臨床實驗數量
    • 北美主要國家的臨床實驗數量
    • 中東·非洲主要5個國家的臨床實驗數量
    • 中南美主要5個國家的臨床實驗數量

G7各國臨床實驗數量:感染疾病臨床實驗上院內感染性肺炎(HAP)所佔的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:感染疾病臨床實驗上院內感染性肺炎(HAP)所佔的比例

E7各國的各階段臨床實驗數量

E7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

未完成的臨床實驗數量

一定期間所採用的實驗對像

贊助商類別的臨床實驗數量

有潛力的贊助商

院內感染性肺炎(HAP)治療藥臨床實驗的主要參與企業

有潛力的藥劑

臨床實驗簡介

  • 主要企業臨床實驗概要
    • AstraZeneca PLC
    • Cubist Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Johnson & Johnson
    • Evolva Holding SA
    • Sanofi
    • KaloBios Pharmaceuticals, Inc.
    • Merck & Co., Inc.
    • Janssen Pharmaceuticals, Inc.
    • Basilea Pharmaceutica AG
  • 有代表性的研究機關·醫院臨床實驗概要
    • University of Thessaly
    • Prince of Songkla University
    • Universite Victor Segalen Bordeaux 2
    • University of Athens
    • Denver Health and Hospital Authority
    • St. Joseph's Hospital and Medical Center
    • Mahidol University
    • Arak University of Medical Sciences
    • Hospital Pablo Tobon Uribe
    • Hamedan University of Medical Sciences

5個有代表性的臨床實驗簡介

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4596CTIDB

GlobalData's clinical trial report, "Hospital Acquired Pneumonia (HAP) Global Clinical Trials Review, H2, 2017" provides an overview of Hospital Acquired Pneumonia (HAP) clinical trials scenario. This report provides top line data relating to the clinical trials on Hospital Acquired Pneumonia (HAP). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 2
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Hospital Acquired Pneumonia (HAP) to Infectious Disease Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Hospital Acquired Pneumonia (HAP) to Infectious Disease Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 20
  • Clinical Trials in E7 Countries by Trial Status 21
  • Clinical Trials by Phase 22
  • In Progress Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 25
  • Subjects Recruited Over a Period of Time 26
  • Clinical Trials by Sponsor Type 27
  • Prominent Sponsors 28
  • Top Companies Participating in Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials 29
  • Prominent Drugs 30
  • Clinical Trial Profile Snapshots 31

Appendix 157

  • Abbreviations 157
  • Definitions 157
  • Research Methodology 158
  • Secondary Research 158
  • About GlobalData 159
  • Contact Us 159
  • Source 159

List of Tables

List of Tables

  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 14
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 15
  • Proportion of Hospital Acquired Pneumonia (HAP) to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 16
  • Hospital Acquired Pneumonia (HAP) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Hospital Acquired Pneumonia (HAP) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Hospital Acquired Pneumonia (HAP) to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 19
  • Hospital Acquired Pneumonia (HAP) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Hospital Acquired Pneumonia (HAP) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Phase, 2017* 22
  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Hospital Acquired Pneumonia (HAP) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30

List of Figures

List of Figures

  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 14
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 15
  • Proportion of Hospital Acquired Pneumonia (HAP) to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 16
  • Hospital Acquired Pneumonia (HAP) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Hospital Acquired Pneumonia (HAP) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Hospital Acquired Pneumonia (HAP) to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 19
  • Hospital Acquired Pneumonia (HAP) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Hospital Acquired Pneumonia (HAP) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Hospital Acquired Pneumonia (HAP) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30
  • GlobalData Methodology 158
Back to Top